Skip to main content
Shawn Yu, MD, Internal Medicine, Chapel Hill, NC

ShawnXiaoYuMDPhD

Internal Medicine Chapel Hill, NC

Hematology/Oncology

Hematology/Oncology Fellow at University of North Carolina

Dr. Yu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Yu's full profile

Already have an account?

  • Office

    170 Manning Drive Cb7305
    Chapel Hill, NC 27599
    Phone+1 919-966-1996

Summary

  • I am a physician scientist trained in hematology/oncology, clinical pharmacology, and protein science, seeking to engineer novel protein-based immunotherapies for the fight against cancer.

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2022 - 2025
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2019 - 2022
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 2019
  • University of Washington
    University of WashingtonPh.D., Bioengineering, 2008 - 2015
  • California Institute of Technology
    California Institute of TechnologyB.S., Chemical Engineering, 2004 - 2008

Awards, Honors, & Recognition

  • Fred J. Ansfield, MD, Endowed Young Investigator Award Conquer Cancer Foundation, American Society of Clinical Oncology, 2024
  • Alexander Grinstein Endowed Fellowship University of Washington, 2009
  • Upper Class Merit Award, Carnation Scholarship California Institute of Technology, 2007-2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Impact of steroid use among patients with renal cell carcinoma (RCC) who develop immune-related adverse events (irAE)
    Peter Zang, Karen Resnick, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Varsha Tulpule, Anishka D'souza, and Gino Kim In, Journal of Clinical Oncology, 6/2/2022
  • Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors
    Karen Resnick, Peter Zang, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Trevor E Angell, Jacob Stephen Thomas, Jorge J. Nieva, and Gino Kim In, Journal of Clinical Oncology, 6/2/2022
  • Venous thromboembolism in patients on check point inhibitors
    Upama Giri, Xiao Yu, Karen Resnick, Travis Larsen, and Gino Kim In, Journal of Clinical Oncology, 5/28/2021

Other

  • De novo design of potent and selective interleukin mimetics 
    Silva Manzano, D. A.; Yu, S.; Ulge, U.; Baker, D.; Garcia, K. C.; Spangler, J.; Walkey, C.; Rubio, A. Q.; Weitzner, B., US 11117944 B2
    https://lens.org/080-135-637-654-248
    9/14/2021

Grant Support

  • Young Investigator AwardConquer Cancer, the ASCO Foundation2024–2025
  • Multispecific T-cell engagers targeting intracellular cancer-testis antigens in urothelial carcinomaNC TraCS2024–2025
  • UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training ProgramNational Institute of General Medical Sciences2023–2024

Research History

  • Postdoctoral FellowUNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program, Brian Kuhlman and William Kim2023 - 2025
  • Postdoctoral FellowUniversity of Washington, David Baker2017 - 2018

Professional Memberships

Other Languages

  • Chinese (Mandarin), Spanish

Industry Relationships

  • Co-Founder, Neoleukin Therapeutics2018 - 2018